SQUARE
e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  6     ISSUE:  1    January 27, 2008 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN, MBBS

 

EDITORIAL

Dear Doctor:

Happy New Year !

Welcome to this edition of 'e-SQUARE' healthcare online !

Our current issue focused on some interesting features like

"Statins And Cardiac Death !", "Bacon, Hot Dogs Alert !", "Infant Vaccine !", "New Cochlear Implant !", "Major Advance In Leukemia !", "Stroke Alert !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals Ltd. as well.

Please send us your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE PHARMACEUTICALS LTD.

 Statin And Cardiac Death !

 Statins Could Reduce Risk Of Sudden Cardiac Death

Results of a new study indicate that the statins used to lower cholesterol levels also help prevent chaotic heart beats that can lead to sudden cardiac death. The study shows that statins are "associated with a significant 19 percent risk reduction for sudden cardiac death." Sudden cardiac death is caused when the heart stops beating suddenly or goes into a disorganized rhythm, or arrhythmia, that cannot sustain blood flow. In contrast, a heart attack occurs when an artery supplying blood to the heart muscle becomes blocked and the heart can no longer pump properly. The researchers analyzed data from 10 large studies, involving 22,275 patients, looking at treatment with statins -- drugs like Atorvastatin or Simvastatin, for example -- and that included information on the occurrence of sudden cardiac death. Over an average follow-up of 4.4 years, the likelihood of sudden cardiac death was 3 percent in patients given statins and 3.8 percent in "control" patients, the researchers reported. The reduction in risk of sudden cardiac death was independent of changes in cholesterol levels. The lead researcher concludes that "part of the clinical benefit of statin treatment could be represented by a decrease in life-threatening arrhythmias."

SOURCE: American Journal of Cardiology, December 2007.

Return to top

 Bacon, Hot Dogs Alert !

Bacon, Hot Dogs May Damage The Lungs

Men who smoke may be increasing their risk of developing emphysema and chronic bronchitis if they eat lots of cured meat, new research shows. Cured meats such as sausage, ham, bologna, bacon and hot dogs contain high levels of nitrites, which are added to prevent rancidity and bacterial growth and enhance a meat's pink color. And just like cigarette smoking and air pollution, nitrites generate molecules known as reactive oxygen and nitrogen species that have been linked to chronic obstructive pulmonary disease (COPD), the researchers noted. The chief risk factor for COPD, which encompasses chronic bronchitis and emphysema, is cigarette smoking. Researchers suggest that eating cured meats may worsen the harmful effects of smoking on risk of COPD. They looked at data on 42,915 men participating in the Health Professionals Follow-up Study, 111 of whom were diagnosed with COPD within 12 years of enrolling in the study. Men who ate cured meats at least once a day were 2.64 times more likely than those who almost never ate cured meats to develop COPD, the researchers found. Cured meat consumption has also been linked to diabetes and certain types of cancer, researcher noted. 

 

SOURCE: Reuters Health, December 2007.

Return to top

 
 
 lnfant Vaccine !

                                                        Meningitis Vaccine For Infants

A meningitis vaccine is now recommended for children 11 to 18 years old. However, that vaccine is not effective in infants. But a new vaccine appears to be safe and effective against four strains of meningococcal disease in infants. The new vaccine is a meningococcal vaccine that uses natural mutant of the diphtheria toxin. The study included 421 healthy infants who received one of three different dosing schedules of vaccine. Authors then determined the number of infants that had antibody levels after receiving the vaccine and looked at vaccine safety. Researchers found infants who received doses at two, three and four months old had protective antibody levels for all four strains. Infants who received doses at two, four and six months had protective antibody levels for three strains but lower for the fourth strain. Study authors say this study shows that this vaccine is well tolerated and effective in the first year of life.

 

SOURCE: Journal of the American Medical Association, January 2008.

Return to top

 
 
 New Cochlear Implant !

New Cochlear Implant Technology Possible

 New and improved cochlear implants may be on the horizon. How well today’s cochlear implants work varies in patients. Some may be able to hear sounds such as thunder. Others can understand speech but are not able to appreciate music. But new research could make it all possible. The implants are surgically placed into the cochlea – the snail-shell shaped structure in the inner ear. Normally hair cells line the cochlea and convert acoustic signals into electrical signals that nerves carry to the brain. Sounds can be amplified with a hearing aid if there are some hair cells. If the hair cells are missing or damaged – which is usually associated with severe hearing problems – an implant can help replace their function. A new study found that two neurotrophin proteins in the cochlea that play a big role in relaying sound messages to the brain and how these proteins operate in the cochlea. Researchers say one end of the cochlea houses faster-firing neurons that carry high pitched sound messages to the brain while the other end rich in the other neurotrophin makes those neurons slower-firing to transmit lower pitched signals. The researchers mention that it is possible to pump the neurotrophins into a newly-designed cochlear implant and release them through ports.

SOURCE: Ivanhoe Newswire, January 2008.

Return to top

 
 
 Major Advance in Leukemia !

Major Step Ahead In Treating Leukemia

Researchers have discovered a pathway that makes cancerous leukemia cells resistant to treatment. The discovery is the first step in developing new drugs that could significantly improve survival rates for victims of Acute Myeloid Leukemia (AML). Acute Myeloid Leukemia attacks white blood cells and is a common form of the disease in children and adults. The current treatment is a range of chemotherapy drugs but many patients need bone marrow transplants because the AML cells are death resistant. AML cells get their resistance through a genetic anti-oxidant pathway called hemoxygenase-1 or HO-1. HO-1 is the reason the cells don’t die. It protects them from damage making the cytotoxic agents in chemotherapy drugs ineffective. The team found that the drug resistant cells have overactive ARE genes which include HO-1 which is why they can’t be killed. Blocking this pathway allows the cells to respond normally. “This is a major step forward in the treatment of leukemia and other cancers,” said the lead researcher. “The next step will be a program to develop a new set of targeted therapies to treat not only Acute Myeloid Leukemia, but other leukemias and other cancers,” he added.

  

SOURCE: Blood, January 2008.

Return to top

 
 
 Stroke Alert !

High Triglycerides, Other Cholesterol Raise Stroke Risk

High triglycerides and another kind of cholesterol may raise the risk of a certain type of stroke. LDL or “bad” cholesterol is the main target for reducing stroke risk. But new research finds other types of cholesterol may be more strongly linked with the risk of stroke; specifically non-high density lipoprotein cholesterol – a type of cholesterol tested but not usually evaluated in a risk assessment. It is considered neither the “good” nor the “bad” cholesterol. The study analyzed the records of 1,049 patients admitted to hospital with a mini-stroke over four years. 247 of them had a large artery atherosclerotic stroke – a type of ischemic stroke caused by a blockage in the large arteries leading to the brain. Results show participants with high triglycerides and elevated non-high density lipoprotein cholesterol were more likely to have a large artery atherosclerotic stroke than those with low levels. Patients with the highest triglycerides were 2.7 times more likely to have this type of stroke than those with the lowest level. Those with the greatest non-high density lipoprotein cholesterol were 2.4 times more likely. Researchers found people with high LDL cholesterol did not have an increased risk of this type of stroke. But they say it is still important to monitor levels to reduce the risk of other types of stroke and heart disease.

 

SOURCE: Neurology, December 2007.

Return to top

 
 

New Products of SQUARE Pharmaceuticals Ltd.

  Product Nidipro®
  Generic Name Nifedipine BP + Atenolol BP
  Strength 20 mg SR + 50 mg IR
  Dosage form Capsule
  Therapeutic Category Calcium Antagonists Combination
  Product Sultolin Refill®
Generic Name Salbutamol BP
Strength 100 mcg/puff
Dosage form Metered Dose Inhaler
Therapeutic Category Antiasthma
  Product Angivent MR® 
  Generic Name Trimetazidine HCL
  Strength 35 mg
  Dosage form Tablet
  Therapeutic Category Antianginal

Return to top

 

Copyright © 2008 SQUARE Pharmaceuticals Ltd. All rights reserved